Literature DB >> 1487767

Community hospital experience with recombinant tissue plasminogen activator in acute myocardial infarction.

S M Austin1, M Caro, D Gemmel.   

Abstract

Clinical features, outcomes, and hospital charges of 51 consecutive patients who had had acute myocardial infarction (MI) and who had received intravenous tissue plasminogen activator (TPA) at a community teaching hospital were reviewed retrospectively. The overall mortality rate was 22%, including four patients (8%) who had died of hemorrhagic complications, three of whom (6%) had had intracerebral hemorrhages. Despite similar mean ages and lengths of hospital stay, TPA patients had had significantly higher total hospital charges and ancillary charges than had had concurrent MI patients who had not received TPA (p less than 0.0001). In a community hospital setting, older patients may be at higher risk for intracranial hemorrhage when treated with TPA, especially in the presence of other risk factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487767     DOI: 10.1007/bf02598010

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  20 in total

Review 1.  Prognosis and management after a first myocardial infarction.

Authors:  A J Moss; J Benhorin
Journal:  N Engl J Med       Date:  1990-03-15       Impact factor: 91.245

2.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

3.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.

Authors:  A D Guerci; G Gerstenblith; J A Brinker; N C Chandra; S O Gottlieb; R D Bahr; J L Weiss; E P Shapiro; J T Flaherty; D E Bush
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

4.  Coronary thrombolysis in a community hospital: experience with an intravenous streptokinase protocol.

Authors:  H G Morse; W J Epperson; J M Kovaz; J D Ware; S M Barnes; J E Bleckley; W W Walker; F G Jones
Journal:  South Med J       Date:  1988-06       Impact factor: 0.954

5.  Short-term risk stratification at admission based on simple clinical data in acute myocardial infarction.

Authors:  C Dubois; L A Pierard; A Albert; J P Smeets; J C Demoulin; J Boland; H E Kulbertus
Journal:  Am J Cardiol       Date:  1988-02-01       Impact factor: 2.778

6.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

7.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

8.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.

Authors:  H D White; J T Rivers; A H Maslowski; J A Ormiston; M Takayama; H H Hart; D N Sharpe; R M Whitlock; R M Norris
Journal:  N Engl J Med       Date:  1989-03-30       Impact factor: 91.245

9.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

10.  A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days.

Authors: 
Journal:  N Engl J Med       Date:  1986-06-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.